Dr. Sabbagh is a widely recognized key opinion leader in Alzheimer’s disease and has led a large number of clinical trials in the field, ranging from early Phase 1–2 studies to larger registration trials. In his role as Global Principal Investigator, he will contribute to the overall study design, support local investigators, and serve on the study’s steering committee for the Phase 2 study of ALZ-101.

Alzinova’s vaccine candidate ALZ-101 has, in the finalized Phase 1b study, demonstrated a favorable safety and tolerability profile, as well as a strong immune response against Aβ oligomers, with exploratory biomarker data and clinical observations indicating a potential disease‑modifying effect in patients with Alzheimer’s disease. Dr. Sabbagh’s scientific and clinical experience complements the company’s expertise and strengthens Alzinova’s organization as the program advances to the next stage of development.

Dr. Marwan Sabbagh comments:
“Alzinova’s Phase 1b study with ALZ-101 has shown a good safety profile, robust immune response, and promising explorative data. I look forward to working closely with the team to design and conduct a Phase 2 study that can confirm these results and bring us one step closer to new treatment options for patients with Alzheimer’s disease.”

As part of the collaboration, Dr. Sabbagh has chosen to receive the majority of the agreed compensation in shares of Alzinova. This creates a clear alignment of interest between the company and Dr. Sabbagh as the clinical development progresses.

Tord Labuda, CEO of Alzinova, comments:
“Dr. Sabbagh brings deep clinical experience from numerous Alzheimer’s studies and a strong international network within the field, which is crucial as we now enter a more operational phase of development. Our focus is to conduct a robust and well-planned Phase 2 study with ALZ-101, and his engagement as Global Principal Investigator strengthens our ability to deliver on that ambition.”

Facts about Dr. Marwan Sabbagh

• Professor of Neurology and internationally recognized Alzheimer’s disease expert.
• Board-certified behavioral neurologist.
• Fellow of the American Academy of Neurology (FAAN).
• Clinical Alzheimer’s researcher with an extensive publication record and thousands of citations in dementia, Alzheimer’s disease, and clinical trials.
• Has served as principal investigator and advisor in multiple international clinical trials of disease-modifying treatments for Alzheimer’s disease.

For further information, please contact:
Tord Labuda, CEO
E-mail: info@alzinova.com

About Alzinova AB
Alzinova AB is a Swedish biopharmaceutical company in clinical development specializing in the treatment of Alzheimer's disease, where the starting point is to attack toxic amyloid-beta oligomers. The lead candidate ALZ-101 is a therapeutic vaccine against Alzheimer's disease. Alzinova's patented AβCC peptide technology makes it possible to develop disease-modifying treatments that target the toxic amyloid-beta oligomers that are central to the onset and development of the disease with great accuracy. From a global perspective, Alzheimer's disease is one of the most common and devastating neurological diseases, with around 55 million affected today. Based on the same technology, the company is also developing the antibody ALZ-201, which is currently in preclinical development, and the goal is to further expand the pipeline. The company's Certified Adviser on Nasdaq First North Growth Market is Mangold Fondkommission AB. For more information about Alzinova, please visit: www.alzinova.com